# A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

> **NCT01723020** · PHASE1 · COMPLETED · sponsor: **Kartos Therapeutics, Inc.** · enrollment: 107 (actual)

## Conditions studied

- Advanced Malignancy
- Advanced Solid Tumors
- Cancer
- Oncology
- Oncology Patients
- Tumors
- Glioblastoma
- Multiple Myeloma

## Interventions

- **DRUG:** AMG 232

## Key facts

- **NCT ID:** NCT01723020
- **Lead sponsor:** Kartos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-27
- **Primary completion:** 2017-03-15
- **Final completion:** 2017-09-25
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2021-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723020, "A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT01723020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*